Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030
Journal of Clinical Oncology (Impact Factor: 18.43). 08/2012; 30(27):3345-52. DOI: 10.1200/JCO.2011.40.8120
Source: PubMed


Platinum resistance is a major limitation in the treatment of advanced non-small-cell lung cancer (NSCLC). Reduced intracellular drug accumulation is one of the most consistently identified features of platinum-resistant cell lines, but clinical data are limited. We assessed the effects of tissue platinum concentrations on response and survival in NSCLC.

Patients and methods:
We measured total platinum concentrations by flameless atomic absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. Tissue platinum concentration was correlated with percent reduction in tumor size on post- versus prechemotherapy computed tomography scans. The relationship between tissue platinum concentration and survival was assessed by univariate and multicovariate Cox proportional hazards regression model analysis and Kaplan-Meier analysis.

Tissue platinum concentration correlated significantly with percent reduction in tumor size (P < .001). The same correlations were seen with cisplatin, carboplatin, and all histology subgroups. Furthermore, there was no significant impact of potential variables such as number of cycles and time lapse from last chemotherapy on platinum concentration. Patients with higher platinum concentration had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model analysis after adjusting for number of cycles.

This clinical study established a relationship between tissue platinum concentration and response in NSCLC. It suggests that reduced platinum accumulation might be an important mechanism of platinum resistance in the clinical setting. Further studies investigating factors that modulate intracellular platinum concentration are warranted.

19 Reads
  • Source
    • "Penetrance of cisplatin into tumour tissue differs in different cancers. However, the concentration of cisplatin and its analogues positively correlates with reduction of tumour mass and clinical parameters, such as recurrence free and overall survival, e.g. in non-small-cell lung cancer (Kim et al., 2012). Cisplatin enters the cells either passively by a simple diffusion or by active protein-mediated transport systems, e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Metal-based coordination compounds have been used throughout the history of human medicine to treat various diseases, including cancer. Since the discovery of cisplatin in 1965, a great number of metal coordination complexes, such as platinum, ruthenium, gold or copper have been designed, synthesized and tested in order to develop clinically effective and safe drugs. Currently, many reviews cover applications of cytostatic metal complexes pointing out the most promising examples of platinum- and non-platinum-based compounds in preclinical and clinical trials. However, recent comprehensive reviews covering chemical and biological aspects of metal-based coordination compounds in cancer therapy are still rare. In this review we wish to provide an overview of the coordination chemistry of current and novel cytostatic compounds, including an outline of their design and rationale of synthesis, and summarize bio-chemical reactivity and physicochemical properties of candidate metal complexes.
    Full-text · Article · Mar 2015 · Journal of applied biomedicine
  • Source
    • "A recent study has established a significant correlation between intracellular platinum buildup and reduction in tumor size [67]. It was previously thought that the dominant mode for cisplatin's entry into tumor cells was through passive diffusion [66], but growing evidence has supported the role of copper transporters in the active influx and efflux of cisplatin [67]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer (NSCLC) as the standard of care. However, therapeutic outcomes vary from patient to patient. Considerable efforts have been invested to identify biomarkers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based treatment could be improved by the use of these biomarkers.
    Full-text · Article · Oct 2014 · Genomics Proteomics & Bioinformatics
  • Source
    • "Our results also support the previous findings that decreased platinum accumulation in NSCLC tumor tissues might be an important mechanism of platinum resistance in patients with NSCLC [13]. Compared with a median survival of 5.2 months produced by docetaxel and 9.4 months by selumetinib plus docetaxel in patients with platinum-pretreated KRAS-mutant NSCLC, the median survival of 9.5 months by our combination treatment shows promising potential [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Efficacy of second-line chemotherapy in platinum-pretreated non-small cell lung cancer (NSCLC) is poor. This study investigated efficacy of computed tomography-guided percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection (CT-PFNECII) combined with second-line chemotherapy in patients with platinum-pretreated stage IV NSCLC. Between October 2011 and July 2013, 34 eligible patients were randomly assigned to receive either CT-PFNECII combined with second-line chemotherapy (combination group, n = 17) or second-line chemotherapy alone (chemotherapy group, n = 17). The primary end points were the proportions of patients who achieved an overall response rate (ORR) and disease control rate (DCR). Secondary end points were median survival and progression-free survival (PFS). The ORR and DCR in the combination group were significantly higher than in the chemotherapy group (23.53% vs 11.76% for ORR, P < .01; and 58.82% vs 35.29% for DCR, P < .01). Compared with patients in the chemotherapy group, patients in the combination group had significantly longer PFS (5.4 months vs 3.0 months, P < .01) and median survival (9.5 months vs 5.3 months, P < .01). CT-PFNECII combined with second-line chemotherapy provided a higher response rate and improved survival than second-line chemotherapy for patients with platinum-pretreated stage IV NSCLC.
    Full-text · Article · Mar 2014 · Translational oncology
Show more